Global Natural Killer (NK) Cell Therapeutics Market Trends, Companies & Clinical Trials Insight 2023 Report Highlights:
• Global Natural Killer (NK) Cell Therapeutics Market Trends Insight
• Partnerships & Funding for Natural Killer Cell Therapies : > 10 Recent Deals
• Global Natural Killer Cell Therapies Clinical Trials Insight: > 200 Therapies
• Global Natural Killer Cell Therapies Clinical Trials By Company, Indication & Phase
• Proprietary Technologies By Company Insight: > 10 Technologies
• FDA Fast Track & Orphan Designation insight
• Detailed Outlook On More than 30 Companies
Progressing from surgery and chemotherapies, the landscape of cancer treatment has witnessed a lot of development; however, significant growth was when immunotherapy was introduced in its treatment regimen. With the new era of cancer immunotherapy, the use of Chimeric Antigen Receptor (CAR) T-cells has been applied with other possible approaches like NK (natural killer) cells. Pre-clinical research has shown promising potential in this approach of CAR modified NK cells, further triggering clinical studies to be conducted.
Treatment using natural killer cells is an emerging therapeutic segment in the field of cancer immunotherapy which has generated a considerable amount of interest from researchers and the pharmaceutical industry. Consequently, the fascinated attention in the topic has resulted in development of robust clinical channel. Having advantage over existing cell therapies, NK cells have the potential show progress in case of solid tumors as success has been witnessed in case of hematological cancers, though little evolvement has been achieved in solid tumors.
Moreover, the combined use of NK cells with CAR has the ability to show benefits in comparison to NK cells alone. With spontaneous cytotoxic activity of NK cells to generate target cell death and having the ability to specifically target tumor cells using T lymphocytes by CAR-specific mechanism, this approach has been turning heads. Nevertheless, more clinical trials are required to confirm the overpowering benefit of CAR-NK cell therapy but the hope is positive as pre-clinical studies have been demonstrating promising outcomes.
Pharma companies have begun their journey to develop proprietary technologies so as to maintain and lead this emerging market of CAR-NK cell therapies. Recently, Cellinfinity Bio has announced publication and licensing of key technology for directed evolution of cells that allows for more effective cell therapy. The company’s CLASH technology, a platform that enables massive parallel genomic knock-in into human cells, allows the creation of a large library of precisely engineered cellular variants, enabling rapid and efficient selection of cells with desired properties for effectively engineered cell therapies against a variety of disorders.
Due to the current CAR-NK cell therapies having certain limitations, Cellinfinity Bio thinks that their proprietary unbiased evolution technology CLASH will allow to find universal modifications that can overcome many problems of current cell therapy regimen. Cellinfinity Bio now has exclusive rights to the CLASH technology and the identified genetic modifications.
Currently, the market of CAR-NK cell therapies is at nascent stage as there has been no therapy approved by the US FDA. With several pharmaceutical companies aiming to launch their novel CAR-NK cell therapeutics, the future of this blossoming market looks flourishing. Furthermore, the adoption of these next-generation cancer immunotherapies by the pharma sector, patient segment and the supporting government guidelines, promise that this approach will be thriving in the cancer immunotherapy market. Some of the key frontrunners in this market segment include; Affimed NV, GC Cell, Takeda Pharmaceuticals, Glycostem Therapeutics and others.
The market penetration and reach of CAR-NK cell therapies if compared to existing adoptive cell therapies holds a promising future. It can be predictable that in the coming future, the first CAR-NK cell therapy to enter the market will certainly shift the treatment paradigm of cancer. However, for now, it can only be hoped and anticipated that when that time comes, the market segment shows the predicted growth. With pharmaceuticals targeting the “first movers” advantage, there are several therapies in clinical and preclinical pipeline.
Being a distinctive approach, the introduction of CAR-NK cell therapy is said to change the treatment landscape of not only cancer but other disorders as well. This report aims to provide an in-depth analysis about the current market scenario of this budding therapeutic market as well as information about the ongoing progress seen in the clinical trials. Interest in this segment has escalated the number of collaborations, in order to increase their portfolio. Our report also provides insights on company collaborations being made, so as to gain an upper edge in the market, these include collaborations, agreements, partnerships, alliances, technology exchange or in-licensing deals.